Similarly, preliminary data from a trial involving the administration of MEDI4736 to different tumour types showed an overall response rate of 14% in 22 patients with head and neck cancer, including a response rate of 50% in those whose tumours were PD-L1 positive vs. 6% in those whose tumours were PD-L1 negative [89]. This evidence concerns the gene CD274 and neoplasm.